Cutting costs on mono-resistant tuberculosis diagnosis could eventually end up being more expensive.
F
F
Rouzaud
J
J
Robledo
D000995:Antitubercular Agents / Q000494:pharmacology*; D003470:Culture Media / Q000737:chemistry / Q000191:economics*; D024881:Drug Resistance, Bacterial; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests / Q000191:economics / Q000379:methods; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D014376:Tuberculosis / Q000175:diagnosis* / Q000188:drug therapy / Q000191:economics; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics
D000995:Antitubercular Agents; D003470:Culture Media; D007538:Isoniazid; D012293:Rifampin